Healthcare

Radiotheranostics Market Forecast 2024-2033: Growth Rate, Drivers, And Trends

The Radiotheranostics Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Radiotheranostics Market:

https://www.thebusinessresearchcompany.com/report/radiotheranostics-global-market-report

According to The Business Research Company’s Radiotheranostics Global Market Report 2024, The radiotheranostics market size has grown rapidly in recent years. It will grow from $7.57 billion in 2023 to $8.74 billion in 2024 at a compound annual growth rate (CAGR) of 15.3%. The growth in the historic period can be attributed to advancements in nuclear medicine, rise in cancer cases, personalized medicine development, advances in radiopharmaceuticals, regulatory approvals and standards.

The radiotheranostics market size is expected to see rapid growth in the next few years. It will grow to $14.61 billion in 2028 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to advancements in targeted cancer therapies, expansion in oncology research, rise in chronic diseases, growth in theranostic applications. Major trends in the forecast period include theranostic radiopharmaceutical development, expanding applications beyond oncology, personalized radiopharmaceuticals, nanotechnology in radiotheranostics, regulatory shifts and standardization.

The increasing prevalence of cancer is expected to propel the growth of the radiotheranostics market going forward. Cancer is a condition in which some cells in the body develop uncontrollably and spread to other regions of the body. Radiotheranostics medicines are commonly employed in cancer to offer the ultimate notion of customized medicine by using paired diagnostic and therapeutic radionuclide probes for the selective and targeted detection and treatment of specific (typically cancer) cells, each of which is suited to the patient’s underlying condition to enhance treatment efficiency and better clinical output. For instance, according to Cancer Research UK, a UK-based cancer research organization, approximately 18 million new cancer cases were detected in 2020. Further, there would be 28 million new cancer cases globally each year by 2040, a 54.9% increase over 2020, and is predicted to be more prominent in males (60.6% increase) than girls (48.8% increase). Therefore, the increasing prevalence of cancer drives the radiotheranostics market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=12270&type=smp

The radiotheranostics market covered in this report is segmented –

1) By Radioisotope: Technetium-99, Gallium-68, Iodine-131, Iodine-123, Fludeoxyglucose-18F, Yttrium-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Other Radioisotopes

2) By Approach: Targeted Therapeutic, Targeted Diagnostic

3) By Application: Oncology, Non-Oncology

4) By End-Users: Hospitals and Clinics, Pharmaceutical and Biotechnology Companies, Other End-Users

Product innovations are a key trend gaining popularity in the radiotheranostics market. Significant companies are concentrating their efforts on creating innovative products to strengthen their position in the market. For instance, in May 2023, Advanced Cyclotron Systems Inc., a Canada-based company that supplies and services cyclotrons predominantly used for producing medical isotopes, introduced TR-ALPHA for producing alpha-emitting radioisotopes to treat cancer. It is an appropriate solution to the market demand for a low-cost cyclotron capable of producing vast amounts of Astatine-211, one of the most promising alpha-emitting radioisotopes. The TR-ALPHA is also far smaller, less costly, and simpler to run than previous cyclotron models capable of manufacturing alpha-emitting radioisotopes. It is the ideal solution for hospitals, researchers, and institutions interested in running a dedicated cyclotron to efficiently produce enormous amounts of therapeutic alpha-emitting radioisotopes.

The radiotheranostics market report table of contents includes: